{"id":20243,"date":"2023-09-27T08:22:29","date_gmt":"2023-09-27T06:22:29","guid":{"rendered":"https:\/\/ggba.swiss\/?p=20243"},"modified":"2023-09-27T08:22:31","modified_gmt":"2023-09-27T06:22:31","slug":"top-stories-from-western-switzerland-july-september-2023","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/top-stories-from-western-switzerland-july-september-2023\/","title":{"rendered":"Top Stories from Western Switzerland (July-September 2023)"},"content":{"rendered":"\n

Seven Western Switzerland start-ups awarded the Solar Impulse Label<\/a><\/h4>\n\n\n\n

The Solar Impulse Foundation awarded seven Western Switzerland start-ups with the Efficient Solution Label, recognizing eco-innovative solutions. Among them, Green-Y Energy optimizes energy consumption, Urbio aids in building decarbonization, and Simon + Josef foster resource savings in hospitality. Zaphiro enhances renewable integration with SynchroGuard, Sun Ways proposes removable solar plants between railway tracks, TreaTech transforms waste into renewable resources, and Enerdrape utilizes geothermal panels to revolutionize building heating and cooling systems. This label not only honors their environmental and economic efficiency but also elevates these start-ups to a platform of international acclaim.<\/p>\n\n\n\n

CSEM helps create the world\u2019s most efficient photovoltaic panels<\/a><\/h4>\n\n\n\n

CSEM, participating in the Hiperion project, has innovated in creating the world’s most efficient solar panels, boasting over 29% power conversion efficiency, significantly higher than the conventional 15-22%. Funded by a EUR 10.6 million grant from the European Union, Hiperion\u2019s hybrid panels ingeniously merge conventional and concentrated photovoltaic technologies, optimizing power production in varying sunlight conditions. Currently in pilot production in Neuch\u00e2tel, these panels are sent across Europe for extensive testing. Targeting niche markets, Hiperion\u2019s panels are ideal for space-constrained areas with high power needs, like urban rooftops and EV charging stations, potentially marking a shift in Europe’s stance in the global photovoltaic industry.<\/p>\n\n\n\n

UNIGE researchers lead breakthrough in understanding tumor growth<\/a><\/h4>\n\n\n\n

Researchers from the University of Geneva (UNIGE) have made a significant discovery that could lead to personalized cancer treatments by identifying how two genes, CXCL9 and SPP1, affect cancer progression within the tumor microenvironment. These genes, expressed by immune cells called macrophages, were found to either accelerate or decelerate cancer progression. By analyzing 52 head and neck tumors individually rather than aggregating cells from different patients, the team observed a critical impact on tumor progression based on the expression of these genes. High CXCL9 expression relative to SPP1 led to better clinical outcomes, opening a potential pathway for targeted cancer treatments by interfering therapeutically with these networks.<\/p>\n\n\n\n

Michelin\u2019s \u201cmade in Fribourg\u201d WISAMO sail revolutionizes sustainable shipping<\/a><\/h4>\n\n\n\n

Michelin’s Wing Sail Mobility (WISAMO) project is pioneering sustainable shipping with its innovative sail installed on a ship traversing between Spain and England. Developed in Michelin’s Givisiez research center, the telescopic, inflatable, and automated WISAMO sail aims to boost shipping efficiency and lessen resource use. Initial tests on Lake Neuch\u00e2tel were successful, with ongoing enhancements to enlarge the sail from 13 to around 60 meters, aiming to cut fuel consumption by 10-20% by 2026-2027. The project, awarded the “Solar Impulse Efficient Solution” label, underscores Michelin\u2019s commitment to eco-friendly transport solutions, aligning with broader efforts towards sustainable maritime transport.<\/p>\n\n\n\n

Nanomedicine pioneer AlphaOnco Swiss achieves remarkable patent ranking<\/a><\/h4>\n\n\n\n

AlphaOnco Swiss, supported by its parent company Nanobacterie, is pioneering nanomedicine-based cancer treatments, with Nanobacterie achieving fourth-place in nanomedicine patent rankings by Marks and Clerk. Nanomedicine enhances drug efficacy and reduces side effects by delivering therapeutic agents directly to the disease site. This Franco-Swiss collaboration is notable in the competitive medical research field, especially given Nanobacterie’s small size. AlphaOnco Swiss is currently seeking investors to advance its innovative cancer treatments further. The longstanding collaboration with Switzerland, known for its innovation and biotechnological research, provides a conducive environment for AlphaOnco Swiss\u2019s groundbreaking endeavors in cancer care.<\/p>\n\n\n\n

\n